A continuous 13C methacetin breath test for noninvasive assessment of intrahepatic inflammation and fibrosis in patients with chronic HCV infection and normal ALT by Lalazar, G et al.
A continuous
13C methacetin breath test for noninvasive
assessment of intrahepatic inﬂammation and ﬁbrosis in
patients with chronic HCV infection and normal ALT
G. Lalazar,
1 O. Pappo,
2 T. Hershcovici,
1 T. Hadjaj,
1 M. Shubi,
1 H. Ohana,
1 N. Hemed
1 and
Y. Ilan
1 1Liver Unit, Department of Medicine; and
2Department of Pathology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Received October 2007; accepted for publication February 2008
SUMMARY. Up to 30% of patients with hepatitis C virus
(HCV) infection and normal serum alanine aminotrans-
ferase (NALT) have signiﬁcant liver disease. Currently,
many of these patients undergo a liver biopsy to guide
therapeutic decisions. The BreathID
  continuous online
13C-methacetin breath test (MBT) reﬂects hepatic micro-
somal function and correlates with hepatic ﬁbrosis. To
assess its role in identifying intrahepatic inﬂammation and
ﬁbrosis in NALT patients, we tested 100 patients with
untreated chronic HCV infection, and 100 age- and sex-
matched healthy volunteers using
13C MBT following
ingestion of 75 mg methacetin. All HCV patients had
undergone a liver biopsy within 12 months of performing
the MBT. Patients with a necroinﬂammatory grade £4o r
>4, based on Ishak (modiﬁed HAI) score, HAIa +
HAIb + HAIc + HAId, were deﬁned as having low or high
inﬂammation, respectively. Patients with a histological
activity ﬁbrosis stage £2 or >2, were deﬁned as having
nonsigniﬁcant or signiﬁcant ﬁbrosis, respectively. A
proprietary algorithm to differentiate intrahepatic inﬂam-
mation within chronic HCV patients with NALT achieved
an area under the curve (AUC) of 0.90. Setting a threshold
on the point of best agreement (at 83%) results in 82%
sensitivity and 84% speciﬁcity. With application of another
proprietary algorithm to differentiate patients with non-
signiﬁcant or signiﬁcant ﬁbrosis, 67% of liver biopsies
performed in the patient group could have been avoided.
This algorithm achieved an AUC of 0.92, with a sensitivity
of 91% and a speciﬁcity of 88%. There was no correlation
between body mass index (BMI) and MBT scores for
patients with the same histological score. The continuous
BreathID
  13C MBT is an accurate tool for measuring the
degree of inﬂammation and ﬁbrosis in patients with
chronic HCV infection and NALT. As such, it may prove to
be a powerful, noninvasive alternative to liver biopsy in
the management of this patient population.
Keywords: breath test, liver ﬁbrosis, methacetin, normal ALT.
INTRODUCTION
The natural history of chronic hepatitis C virus (HCV)
infection is variable, and some carriers have an indolent
disease course with no complications even after decades of
follow-up [1,2]. The decision to start treatment for chronic
HCV infection depends on several factors, including: alanine
aminotransferase (ALT) [3] levels, viral load, liver biopsy
parameters of ﬁbrosis and inﬂammation, patient determi-
nation and expected compliance [4]. The protracted course
of the illness coupled with the intention of treating those
who are most likely to beneﬁt makes liver biopsy an
important decision-making tool.
Serum ALT concentration, the most widely used indirect
marker for liver disease activity, remains within the normal
range in 25–30% of chronic HCV carriers, and an additional
40% have ALT levels less than twice the upper limit of
normal [3,5]. It is generally accepted that the natural history
of the subgroup of HCV carriers with persistently normal or
minimally elevated ALT levels (NALT) is characterized by a
slower progression rate [6–8]. Accordingly, follow-up and
deferring therapy has been suggested in this patient group.
A recent review of three large randomized trials has shown
that patients with NALT have signiﬁcantly lower inﬂam-
mation and ﬁbrosis scores on liver biopsy than patients with
OnlineOpen:This article is available free online at www.blackwell-synergy.com             
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progressive liver disease and develop advanced ﬁbrosis or
cirrhosis [3,10]. These studies suggest that patients with
chronic HCV with NALT should be evaluated similarly to
patients with elevated ALT levels because they are at risk for
developing signiﬁcant liver disease [9].
Using periodic liver biopsies to determine if and when
to use antiviral treatment is unlikely to elicit a favourable
patient response and can lead to higher costs, increased
cumulative cirrhosis incidence and decreased survival rates
in comparison with empirically based treatments [11,12].
Although considered the gold standard for assessment of
liver ﬁbrosis, liver biopsies have limitations, including
inter-observer variability, sampling error and risks for com-
plications. Reliable and inexpensive noninvasive methods to
assess disease progression are a necessity in this setting [12].
Breath testing is based on the principal that an ingested
substrate is metabolized, and a measurable metabolite is
then expelled by the respiratory system. An ideal compound
for this purpose is metabolized solely by the liver and
therefore reﬂects liver function. Breath testing has been used
experimentally and clinically for several decades [10],
including for follow-up on patients with chronic liver
disorders. The major drawbacks of these tests are the need
for traditional, cumbersome isotopic ratio mass spectrometry
methods, a prolonged testing time and patient inconve-
nience.
The BreathID
  continuous online
13C-methacetin breath
test (MBT), which reﬂects hepatic microsomal function
(CYP1A2), is a laser-based technology that creates an
infrared emission precisely matching the absorption spec-
trum of CO2 and can detect variations of less than 1/1000 in
the
13CO2/
12CO2 ratio measurement. The system is based on
the measurement of CO2 by molecular correlation spectros-
copy. This test offers several advantages: It is an ofﬁce-based,
noninvasive tool for the assessment of both liver inﬂamma-
tion and ﬁbrosis does not involve a blood test and can pro-
vide an immediate result at the point-of-care. The aim of the
present study was to determine its accuracy in assessing the
degree of liver ﬁbrosis and inﬂammation in patients with
chronic HCV infection and NALT.
METHODS
Study population
Patients. From 1 March 2006 to 31 May 2006, we enrolled
100 consecutive, unselected, patients with previously
untreated, chronic HCV. All were anti-HCV and HCV RNA
positive, with a normal serum ALT level (£·2 ULN) on two
separate tests during the preceding 6 months. All patients
underwent a thorough physical examination and liver
ultrasonography. Patients with ALT >·2 times the upper
limit of the reference range were excluded. Patients were
enrolled if they fulﬁlled the above criteria and had
undergone a liver biopsy within 12 months of the breath
test, as described below. Patients with other concomitant
causes of liver disease such as hepatitis B virus (HBV), HIV,
autoimmune hepatitis, alcohol abuse (excess of 40 g/day)
and hepatocellular carcinoma were excluded from the study.
Ultrasonographic evaluation of the abdomen was performed
in all patients, and those with vessel occlusion were
excluded.
Healthy volunteers. A group of 100 healthy volunteers (57
males and 43 females) were enrolled as controls in the study.
They were screened by medical history, physical
examination, liver ultrasound and routine liver function
tests. All healthy volunteers had blood test results within
normal limits. None had a history of active or previous liver
disease or alcohol or drug abuse, and none were taking
medications.
All participants gave written informed consent to their
participation in the study, which was conducted in strict
adherence to the principles of the Declaration of Helsinki. All
experiments were approved by the Institutional Review
Board committees and the Israel Ministry of Health Com-
mittee for Human Clinical Trials.
Subject characteristics
Tables 1 & 2 show the main clinical, laboratory and histo-
logical characteristics of the patients and healthy volunteers
at the time of liver biopsy, when applicable. The average age
and body mass index (BMI) of the patients (36 females and
64 males) were 46 (SD 13.6; range 19–76) and 25.2 (SD
3.9; range 17.5–34.6), respectively. Difference in gender
distribution between patients and healthy volunteers (chi-
square test) was not signiﬁcant. Comparing age and BMI
between patients and healthy volunteers (t-tests) yields a
signiﬁcant difference (P = 0.0047) for age and a nonsignif-
icant difference (P = 0.306) for BMI. For healthy volunteers,
average age and BMI were 40.7 (SD 12.6, range 18–75) and
24.6 (SD 3.9, range 18–37), respectively. For HCV patients,
Table 1 Characteristics of patients and healthy volunteers
Patients Healthy volunteers
Number 100 100
Male 64 57
Female 34 43
Age 46.3 ± 13.6
(19–76)
40.7 ± 12.6
(18–75)*
BMI (kg/m
2) 25.3 ± 3.95
(17.5–34.6)
24.6 ± 3.9
(18–37)
ALT (IU/mL) 57 ± 23 17.6 ± 8.1*
AST (IU/mL) 60 ± 26 21.3 ± 8.2*
Values are presented as average ± SD (range). *P < 0.01.
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Methacetin breath test in patients with HCV and normal ALT 717Table 2 Patient clinical and laboratory
parameters, divided by gender
Data
Gender
F M Overall
Count age 36 64 100
Average age 43.39 47.50 46.02
SD age 12.93 13.86 13.62
Min age 20.00 19.00 19.00
Max age 62.00 76.00 76.00
Average BMI 25.28 25.14 25.19
SD BMI 4.42 3.67 3.94
Min BMI 18.00 17.51 17.51
Max BMI 34.63 33.95 34.63
Average ALT 50.42 60.48 56.82
SD ALT 21.56 23.40 23.15
Min ALT 13.00 10.00 10.00
Max ALT 87.00 108.00 108.00
Average AST 61.42 58.78 59.74
SD AST 29.68 22.96 25.49
Min AST 19.00 22.00 19.00
Max AST 160.00 137.00 160.00
Average albumin 42.24 42.02 42.10
SD albumin 4.54 6.59 5.91
Min albumin 27.00 4.40 4.40
Max albumin 51.00 54.00 54.00
Average GGTP 48.40 65.07 58.80
SD GGTP 47.10 61.55 56.86
Min GGTP 9.00 13.00 9.00
Max GGTP 215.00 432.00 432.00
Average ALP 83.32 88.76 86.75
SD ALP 33.45 32.11 32.54
Min ALP 43.00 25.00 25.00
Max ALP 202.00 186.00 202.00
Average LDH 458.03 460.75 459.78
SD LDH 123.90 96.54 106.38
Min LDH 348.00 291.00 291.00
Max LDH 1073.00 929.00 1073.00
Average INR 1.02 1.11 1.08
SD INR 0.06 0.21 0.18
Min INR 1.00 1.00 1.00
Max INR 1.28 1.87 1.87
Average HGLB 14.06 15.60 15.04
SD HGLB 1.94 1.44 1.79
Min HGLB 8.60 9.60 8.60
Max HGLB 21.00 18.50 21.00
Average platelets 233.61 198.58 211.45
SD platelets 86.41 68.77 77.17
Min platelets 37.00 50.00 37.00
Max platelets 447.00 459.00 459.00
Average APRI 0.38 0.38 0.38
SD APRI 0.51 0.38 0.43
Min APRI 0.04 0.09 0.04
Max APRI 2.92 2.54 2.92
Average viral load 1 613 078.05 930 740.68 1 166 029.43
SD viral load 3 328 016.91 3 919 405.81 3 710 874.12
Average HAI ﬁbrosis 2.53 3.02 2.84
SD HAI ﬁbrosis 1.52 1.65 1.61
Min HAI ﬁbrosis 0.00 0.00 0.00
Max HAI ﬁbrosis 6.00 6.00 6.00
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718 G. Lalazar et al.average age and BMI were 46.3 (SD 13.6, range 19–76) and
25.3 (SD 4.0, range 17.5–34.6), respectively.
Biochemical analysis
All patients underwent biochemical work-up, including a
complete blood count, aspartate aminotransferase (AST),
ALT(3), alkaline phosphatase, c-glutamyltranspeptidase,
lactate dehydrogenase, albumin, total bilirubin and pro-
thrombin activity. Routine biochemical tests were performed
using commercially available kits. The AST/ALT ratio and
AST/platelet ratio index were calculated. For ALT measure-
ments, an upper normal limit of 53 U/L was used (Table 2).
Viral studies
All patients were found positive for anti-HCV by means of a
third-generation ELISA (AxSYM HCV version 3.0; Abbott
Laboratories, Abbott Park, IL, USA). Qualitative serum HCV-
RNA detection was performed with reverse transcriptase-
polymerase chain reaction in the 5¢-noncoding region of the
HCV genome (Roche COBAS Amplicor HCV Test, version
2.0: Roche Diagnostics, Basel, Switzerland). Quantiﬁcation
was performed using branched DNA with the Bayers VER-
SANT bDNA 3.0 assays (Bayer Diagnostics, Emeryville, CA,
USA). The detection threshold was 3200 copies (615 IU) per
mL. HCV genotyping was performed with INNO-LIPA HCV II
(Innogenetics, Gent, Belgium).
Liver histology
Followingassessmentofprothrombintimeandplateletcount,
patients underwent a percutaneous, ultrasound-guided
liver biopsy under local anaesthesia (lignocaine 1%). Speci-
mens obtained by means of Menghini needles, diameter
1.6 mm, had an average length of 20 ± 5 mm (range,
15–25 mm), and representative according to accepted
standards. Biopsy specimens were ﬁxed with formalin,
embedded in parafﬁn and stained with haematoxylin and
eosin. All sections were reviewed by an expert pathologist
blinded to patient clinical data and breath-test results.
Necroinﬂammatory score was graded using the HAI score
based on periportal or periseptal interface hepatitis (piece-
meal necrosis) (0–4), conﬂuent necrosis (0–6), focal (spotty)
lytic necrosis, apoptosis, and focal inﬂammation (0–4) and
portal inﬂammation (0–4) [13]. Fibrosis was staged using
the Ishak (modiﬁed HAI) ﬁbrosis score on a scale from 0 to 6
[13]. Table 3 shows selected patient data grouped by ﬁbrosis
score.
Noninvasive breath testing
Following an overnight (>8 h) fast, patients and healthy
volunteers were connected to the breath-testing units Bre-
athID
  system (BreathID Ltd, Jerusalem, Israel) via nasal
cannula (IDcircuit
TM), and received 75 mg of N-(4-meth-
oxy-
13C-phenyl)acetamide (methacetin, Isotec) dissolved in
150 mL of water. Breath samples were collected using an
automatic breath sampling unit under continuous capno-
graphic control, before and for 60 min after the labelled
substrate was administered to the patient. The
13CO2/
12CO2
ratios in the breath samples were determined and mapped on
the screen at a high frequency (once every 2–3 min). During
the test period, all patients and healthy volunteers continued
fasting and were at rest to eliminate any variability in CO2
excretion due to the ingestion of food or physical activity.
Table 3 HCV patient population grouped by modiﬁed HAI ﬁbrosis stage for patient data and blood test results
Data
Modiﬁed HAI ﬁbrosis stage
Total 0123456
Count 4 14 32 24 6 10 10 100
Average age 32.25 42.36 41.97 49.21 50.50 53.10 52.20 46.02
SD age 7.37 14.06 13.91 13.27 13.22 10.97 9.98 13.62
Min age 27.00 19.00 20.00 23.00 34.00 35.00 35.00 19.00
Max age 43.00 64.00 70.00 76.00 68.00 74.00 68.00 76.00
Average BMI 21.59 24.61 24.14 26.49 24.26 26.22 27.23 25.19
SD BMI 2.19 4.28 3.61 3.42 3.19 3.54 5.35 3.94
Min BMI 19.13 19.14 17.51 21.04 19.75 20.82 20.06 17.51
Max BMI 24.44 32.41 32.87 34.63 28.37 31.12 33.95 34.63
Average ALT 39.25 41.36 57.87 55.25 62.33 70.20 70.30 56.92
SD ALT 34.65 22.05 20.71 22.25 14.95 27.37 18.60 23.39
Average AST 35.75 45.00 51.52 61.00 67.17 74.20 93.50 59.74
SD AST 11.38 11.38 14.83 28.99 25.54 23.80 25.86 25.49
Average albumin 41.75 44.42 42.96 41.76 43.17 42.56 36.80 42.10
SD albumin 3.86 3.06 3.78 8.98 5.49 3.50 5.20 5.91
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Results obtained from the device were expressed as per-
centage of administered dose of
13C per cent dose recovered
(PDR) and the cumulative PDR (CPDR) percentage of
13C
recovered over time at 10, 15, 20, 30 and 60 min after
ingestion of methacetin, respectively, as well as the PDR
peak and peak time. PDR refers to the rate at which the
13C
substrate is metabolized and is expressed in %/h. PDR
expresses the rate of substrate metabolization derived from
the change in the
13C/
12C ratio, in which the speciﬁc test
details are taken into account, thereby normalizing the
results and making them independent of differences in
weight, height, dose or substrate type and purity [14,15].
CPDR is the numeric integral of PDR and describes the total
amount of substrate metabolized at any given accumulated
time. Data are expressed in units of %/h for PDR and per cent
for CPDR. The BreathID
  device plots the PDR and CPDR in
real-time and provides PDR peak value and peak time.
Statistical analysis
Using Spearmans nonparametric Rho correlation, the cor-
relation between the different breath-test parameters and
modiﬁed Ishak HAI inﬂammation and ﬁbrosis scores, gender,
BMI and age were assessed. Patients were grouped according
to ﬁbrosis scores, using breath-test parameters to compare
between HAI ﬁbrosis scores of £2 vs >2, and HAI inﬂam-
mation scores (HAIa + HAIb + HAIc + HAId) £4 and >4,
respectively. Mann–Whitneys two-samples test and logistic
regression with receiver operating characteristic (ROC)
curve analysis were used to evaluate the ability of different
breath-test parameters and their combination to predict the
severity of ﬁbrosis and inﬂammation. Finally, the repeat-
ability of the test was determined by assessing several
participants more than once during a period of <2 weeks.
Two algorithms which include several breath-test param-
eters and patient data were developed to allow differentiation
of high vs low inﬂammation, and signiﬁcant vs nonsigniﬁcant
ﬁbrosis, with high sensitivities and speciﬁcities while maxi-
mizing the number of liver biopsies identiﬁed as avoidable.
RESULTS
Breath-test parameters signiﬁcantly differentiate grade of
intrahepatic necroinﬂammation in chronic HCV patients
with NALT
The Mann–Whitney two-samples test, used to compare
inﬂammation groups (HAIa + HAIb + HAIc + HAId £ 4 vs
Table 4 Comparing between BT parameters and degree of intrahepatic inﬂammation for HAIa + HAIb + HAIc + HAId £ 4 vs
>4
Breath-test parameters n Mean SD SE
Asymp. sig. (two-tailed)
Mann–Whitney test
PDR peak Low inﬂammation 32 38.295 15.7333 2.7813 0.0063
High inﬂammation 68 28.589 11.1991 1.3581
Peak time Low inﬂammation 32 18.861 7.6213 1.3473 0.0477
High inﬂammation 68 22.831 9.4697 1.1484
PDR10 Low inﬂammation 32 27.274 16.5672 2.9287 0.0148
High inﬂammation 68 18.982 11.5059 1.3953
PDR15 Low inﬂammation 32 33.894 14.8954 2.6332 0.0034
High inﬂammation 68 23.764 12.1687 1.4757
PDR20 Low inﬂammation 32 32.586 11.2144 1.9824 0.0034
High inﬂammation 68 24.602 10.6473 1.2912
PDR30 Low inﬂammation 32 26.339 7.6357 1.3498 0.0170
High inﬂammation 68 21.714 7.7831 0.9438
PDR60 Low inﬂammation 32 14.749 3.8186 0.6750 0.1105
High inﬂammation 68 12.906 3.9964 0.4846
CPDR10 Low inﬂammation 32 2.348 1.5852 0.2802 0.0072
High inﬂammation 68 1.510 0.9802 0.1189
CPDR15 Low inﬂammation 32 4.825 2.7483 0.4858 0.0076
High inﬂammation 68 3.255 1.9102 0.2316
CPDR20 Low inﬂammation 32 7.500 3.6267 0.6411 0.0049
High inﬂammation 68 5.204 2.7542 0.3340
CPDR30 Low inﬂammation 32 12.502 4.7985 0.8483 0.0028
High inﬂammation 68 9.136 4.0145 0.4868
CPDR60 Low inﬂammation 32 22.255 6.4667 1.1432 0.0042
High inﬂammation 68 17.564 6.0341 0.7317
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720 G. Lalazar et al.> 4) for each breath-test parameter, yielded signiﬁcant
(P < 0.005) results for selected breath-test parameters
(Table 4). A binary logistic regression analysis was
performed with high⁄low inﬂammation as the dependent
variable and breath-test parameters as explanatory
variables, controlled by age, BMI and gender.
Breath-test parameters signiﬁcantly differentiate degree of
ﬁbrosis on liver histology in chronic HCV patients with
NALT
Most of breath-test parameters evaluated showed a
statistically signiﬁcant (P < 0.005) difference between the
Table 5 MBT data grouped by ﬁbrosis groupings (nonsigniﬁcant HAIf £ 2⁄signiﬁcant HAIf > 2) including signiﬁcance
Breath-test parameter Fibrosis n Mean SD SE
Asymp. Sig. (two-tailed)
Mann–Whitney test
PDR peak Nonsigniﬁcant 50 36.843 11.3709 1.6081 <0.0001
Signiﬁcant 50 26.547 13.6582 1.9316
Peak time Nonsigniﬁcant 50 19.860 7.2024 1.0186 0.2022
Signiﬁcant 50 23.261 10.4207 1.4737
PDR10 Nonsigniﬁcant 50 25.135 12.6433 1.7880 0.0030
Signiﬁcant 50 18.136 14.1545 2.0017
PDR15 Nonsigniﬁcant 50 31.563 12.3783 1.7506 0.0009
Signiﬁcant 50 22.448 13.8851 1.9636
PDR20 Nonsigniﬁcant 50 31.875 9.8685 1.3956 <0.0001
Signiﬁcant 50 22.438 10.9569 1.5495
PDR30 Nonsigniﬁcant 50 26.842 6.3321 0.8955 <0.0001
Signiﬁcant 50 19.546 7.8717 1.1132
PDR60 Nonsigniﬁcant 50 15.131 3.2787 0.4637 0.0002
Signiﬁcant 50 11.861 4.0458 0.5722
CPDR10 Nonsigniﬁcant 50 2.101 1.2012 0.1699 0.0017
Signiﬁcant 50 1.455 1.2489 0.1766
CPDR15 Nonsigniﬁcant 50 4.404 2.0923 0.2959 0.0017
Signiﬁcant 50 3.110 2.3730 0.3356
CPDR20 Nonsigniﬁcant 50 6.963 2.8366 0.4012 0.0006
Signiﬁcant 50 4.915 3.2934 0.4658
CPDR30 Nonsigniﬁcant 50 11.932 3.7767 0.5341 <0.0001
Signiﬁcant 50 8.495 4.6195 0.6533
CPDR60 Nonsigniﬁcant 50 22.015 4.8239 0.6822 <0.0001
Signiﬁcant 50 16.115 6.7072 0.9485
Table 6 Values of all MBT parameters differed signiﬁcantly between healthy volunteers and subsets of subjects with HCV
infection
MBT parameter Healthy volunteer HCV total Modiﬁed HAIf £ 2 Modiﬁed HAIf ‡ 2
PDR peak 35.31 ± 8.94 31.7 ± 13.53 36.84 ± 11.37 26.55 ± 13.66
Peak time 21.04 ± 7.47 21.56 ± 9.07 19.86 ± 7.2 23.26 ± 10.42
PDR10 23.85 ± 10.78 21.64 ± 13.81 25.14 ± 12.64 18.14 ± 14.15
PDR15 30.63 ± 10.67 27.01 ± 13.87 31.56 ± 12.38 22.45 ± 13.89
PDR20 32.18 ± 8.65 27.16 ± 11.41 31.88 ± 9.87 22.44 ± 10.96
PDR30 27.03 ± 5.29 23.19 ± 8 26.84 ± 6.33 19.55± 7.87
PDR60 15.82 ± 2.6 13.5 ± 4.02 15.13 ± 3.28 11.86 ± 4.05
CPDR10 1.92 ± 0.92 1.78 ± 1.26 2.1 ± 1.2 1.46 ± 1.25
CPDR15 4.12 ± 1.75 3.76 ± 2.32 4.4 ± 2.09 3.11 ± 2.37
CPDR20 6.66 ± 2.44 5.94 ± 3.23 6.96 ± 2.84 4.91 ± 3.29
CPDR30 11.7 ± 3.3 10.21 ± 4.54 11.93 ± 3.78 8.49 ± 4.62
CPDR60 21.9 ± 4.11 19.07 ± 6.52 22.02 ± 4.82 16.12 ± 6.71
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Methacetin breath test in patients with HCV and normal ALT 721two modiﬁed Ishak HAI ﬁbrosis stages. Because therapeutic
decisions are based on the histological level of ﬁbrosis, the
ability of the MBT to stage ﬁbrosis was assessed. The Mann–
Whitney two-sample tests was used to compare the level of
signiﬁcance for each breath-test parameter and the modiﬁed
Ishak HAI ﬁbrosis stage. Patients were grouped into non-
signiﬁcant ﬁbrosis (modiﬁed Ishak HAI stages £ 2, n = 50)
and signiﬁcant ﬁbrosis (modiﬁed Ishak HAI stages > 2,
n = 50) categories. MBT parameters were found to be sta-
tistically signiﬁcant in differentiating both ﬁbrosis groups.
Data are summarized in Table 5. To develop a diagnostic
mathematical model, logistic regression was used with sig-
niﬁcant⁄nonsigniﬁcant ﬁbrosis assessed with the modiﬁed
Ishak HAI ﬁbrosis stages as the dependent variable and
breath-test variables as explanatory variables, controlled by
age, BMI and gender.
Breath-test parameters signiﬁcantly differentiate between
chronic HCV patients with NALT and healthy volunteer
groups
A binary logistic regression model using PDR20 and age
(P < 0.001 for each of the two parameters) showed that the
MBT can differentiate patients and healthy volunteers with
an area under the curve (AUC) of 0.67 (95% CI, 0.59–0.74),
sensitivity of 56% and speciﬁcity of 86% (Table 6, Fig. 1).
Assessment of serum blood test parameters
Laboratory parameters such as ALT, albumin, prothrombin
time, international normalized ratio levels and the
AST⁄platelet ratio index score were analysed for dependence
with the modiﬁed Ishak HAI ﬁbrosis groups. Results are
summarized in Table 7. Since most models using blood-test
parameters to assess liver disease are often based on elevated
ALT values, they failed in the patient population studied in
the present study.
Correlation with patient characteristics
No signiﬁcant correlation was shown between gender and
modiﬁed Ishak HAI ﬁbrosis stages (chi-square analysis,
P = 0.145). When compared by two-tailed t-tests, BMI and
age differed signiﬁcantly (P = 0.004 and P < 0.001,
respectively) between signiﬁcant and nonsigniﬁcant ﬁbrosis
(HAIf < 3 or HAIf ‡ 3). Spearmans Rho correlations
showed that some breath-test parameters were correlated
with age (PDR peak, PDR20, CDPR30, CPDR60) or BMI
(PDR peak, CPDR60).
Repeatability of breath testing
A total of 42 healthy volunteers and 11 patients were
assessed for test repeatability using the within-subject
coefﬁcient of variation of MBT parameters (Table 8). The
number of repetitions per person was between two and six.
Estimations were based on four BT parameters for healthy
volunteers⁄patients separately and for both groups together.
Repeating the breath testing in both patients and in healthy
volunteers (repeats ‡2) resulted in an inter-test variability of
£13% for the PDR peak height (95% CI, 0.11–0.15).
The use of MBT as a tool to avoid the need for liver biopsy
Necroinﬂammation. By using a proprietary algorithm that
includes breath-test parameters, age and other patient data
to differentiate intrahepatic inﬂammation (HAIa + HAIb +
HAIc + HAId £ 4 vs > 4) for chronic HCV patients with
NALT, an AUC of 0.90 was achieved (Fig. 2). Setting a
threshold on the point of best agreement (at 83%) results in
sensitivity of 82% and speciﬁcity of 84%. At the datasets
prevalence of 68%, the positive predictive value (PPV) was
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Fig. 1 A binary logistic regression model using BreathID
and demographic parameters (P < 0.001 for each of the
parameters) showed that the methacetin breath test (MBT)
can differentiate patients and healthy volunteers with an
area under the curve (AUC) of 0.7 (95% CI, 0.626–0.778),
sensitivity of 56% and speciﬁcity of 86%. A binary logistic
regression model using BreathID
  and demographic
parameters (P < 0.001 for each of the parameters) showed
that the MBT can differentiate patients and healthy volun-
teers with an AUC of 0.67 (95% CI, 0.59–0.74), sensitivity
of 56% and speciﬁcity of 86%. Using Charles E. Metz ROC-
KIT 1.1B2 provides the following results: binormal param-
eters and area under the estimated ROC: a, 0.5158; b,
0.5824; area (Az), 0.6721; area (Wilc), 0.6689. Estimated
standard errors (SE) and correlation of these values: SE (a),
0.1256; SE (b), 0.0754; corr (a,b), 0.2129; SE (Az), 0.0384;
SE (Wilc), 0.0380; symmetric 95% CI for a, (0.2697,
0.7619); b, (0.4347, 0.7301); asymmetric 95% CI for Az,
(0.5938, 0.7435).
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722 G. Lalazar et al.92% and the negative predictive value (NPV) was 69%.
Assuming a prevalence of 45.5%, this would lead to a PPV of
82% and an NPV of 85%.
Fibrosis. By using an algorithm that includes breath-test
parameters, age and other patient data, 67% of liver biopsies
performed in the patient group could have been avoided
(Fig. 3). This algorithm achieved an AUC of 0.92, with a
sensitivity of 91% and a speciﬁcity of 88%, a PPV of 88% and
an NPV of 91%. Thirty-four patients were identiﬁed as
having signiﬁcant ﬁbrosis, including four false positives: two
with a HAI ﬁbrosis score of 2, and an additional two with a
score of 1. Thirty-three patients were identiﬁed as having
nonsigniﬁcant ﬁbrosis, including three false negatives: two
with a HAI ﬁbrosis score of 3 and one with a score of 5.
There was no correlation between age or BMI and MBT
scores for patients with the same histological score.
Applying the same proprietary algorithm developed to
differentiate signiﬁcant from nonsigniﬁcant ﬁbrosis on the
healthy volunteer group combined with the signiﬁcant
ﬁbrosis group (n = 150), 67% of the tested subjects
(n = 98) would get an answer (Fig. 4). This algorithm
achieved an AUC of 0.92, with a sensitivity of 91% and a
speciﬁcity of 88%, a PPV of 79% and NPV of 95%. Thirty-
eight subjects were identiﬁed as having signiﬁcant ﬁbrosis,
including eight false positives. Sixty subjects were identiﬁed
as having nonsigniﬁcant ﬁbrosis including three false neg-
atives; two with a HAI ﬁbrosis score of 3 and one with a
score of 5.
Combination of inﬂammation and ﬁbrosis algorithms. Applying
the described inﬂammation algorithm on the subset of
patients analysed by the ﬁbrosis algorithm (67% of the initial
population), resulted in an area under the ROC of 0.89.
When the same threshold was used, sensitivity and
Table 7 Comparison of laboratory results based on ﬁbrosis grouping: signiﬁcance of laboratory tests in differentiating between
high and low ﬁbrosis groups
Breath-test
parameter Fibrosis n Mean SD SE
Asymp. Sig. (two-tailed)
Mann–Whitney test
ALT Nonsigniﬁcant 49 51.633 23.3146 3.3307 0.0453
Signiﬁcant 50 62.100 22.5065 3.1829
AST Nonsigniﬁcant 49 48.367 14.2693 2.0385 <0.0001
Signiﬁcant 50 70.880 29.0542 4.1089
Albumin Nonsigniﬁcant 44 43.250 3.6096 0.5442 0.0921
Signiﬁcant 48 41.050 7.3026 1.0540
GGTP Nonsigniﬁcant 46 41.630 29.7137 4.3810 0.0010
Signiﬁcant 47 75.596 70.8485 10.3343
ALP Nonsigniﬁcant 44 72.180 18.8024 2.8346 0.0001
Signiﬁcant 48 100.104 36.6787 5.2941
LDH Nonsigniﬁcant 41 442.341 60.5077 9.4497 0.3474
Signiﬁcant 46 475.326 133.6057 19.6991
INR Nonsigniﬁcant 46 1.040 0.1434 0.0211 0.0017
Signiﬁcant 49 1.109 0.1977 0.0282
HGLB Nonsigniﬁcant 48 15.031 1.4531 0.2097 0.6087
Signiﬁcant 50 15.040 2.0829 0.2946
APRI Nonsigniﬁcant 48 0.215 0.0912 0.0132 <0.0001
Signiﬁcant 50 0.539 0.5554 0.0785
Platelets Nonsigniﬁcant 48 239.167 59.8023 8.6317 <0.0001
Signiﬁcant 50 184.840 82.9741 11.7343
Table 8 Calculated reproducibility values for selected groups
CV
Lower 95%
bound
Higher 95%
bound
Healthy subjects (n = 42)
PDR peak 0.1259 0.1035 0.1483
Peak divided by time 0.3619 0.3024 0.4213
PDR20 0.1644 0.1355 0.1932
CPDR20 0.2392 0.1983 0.2801
Patients (n = 11)
PDR peak 0.1501 0.1004 0.1997
Peak divided by time 0.3043 0.2079 0.4007
PDR20 0.1771 0.1190 0.2352
CPDR20 0.2362 0.1600 0.3125
All subjects (n = 53)
PDR Peak 0.1317 0.1111 0.1522
Peak divided by time 0.3494 0.2989 0.3999
PDR20 0.1673 0.1415 0.1931
CPDR20 0.2385 0.2027 0.2743
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Methacetin breath test in patients with HCV and normal ALT 723speciﬁcity were 83 and 81% respectively, with PPV and NPV
of 91 and 68%, respectively (Fig. 5).
Applying the described inﬂammation algorithm on the
subset of patients not analysed by the ﬁbrosis algorithm
(33% of the initial population), resulted in an area under the
ROC of 0.96. When the same threshold was used, sensitivity
and speciﬁcity were 82 and 91%, respectively, with PPV and
NPV of 95 and 71%, respectively (Fig. 6).
DISCUSSION
We assessed the ability of the noninvasive, online, continu-
ous
13C-MBT in the detection of signiﬁcant ﬁbrosis and
inﬂammation in patients with HCV. In a cohort of 100
consecutive HCV patients with normal ALT, breath-test
parameters correlated with the level of ﬁbrosis and degree of
inﬂammation as indicated by the modiﬁed Ishak HAI ﬁbrosis
and inﬂammation scores. The breath test accurately differ-
entiated low and high inﬂammation (£4 and >4, 83%). The
MBT achieved a 90% diagnostic accuracy in differentiating
patients with a modiﬁed Ishak HAI ﬁbrosis score £2 and >2
while 67% of the biopsies could have been avoided by
replacing the assessment with the MBT alone.
Methacetin breath testing has been correlated with ﬁbrosis
and overall liver function [16]. Traditionally, this testing
was performed using isotopic ratio mass spectrometry, the
gold standard for MBT. However, a recent study found that a
measurement method with continuous automatic molecular
correlation spectroscopy showed a high correlation with
mass spectroscopy [17]. In addition to being less cumber-
some, the continuous system has an inherent advantage
over mass spectrometry in its ability to identify the PDR peak
and PDR peak time, which are often missed when noncon-
tinuous measurement is used. Furthermore, being fully
automatic and using an internal capnograph, the system
mitigates the risk of potential human errors and ensures that
the appropriate part of the breath sample is collected.
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Fig. 2 Model to differentiate between HAIa + HAIb +
HAIc + HAId £ 4 vs HAIA + HAIB + HAIC + HAID > 4:
A proprietary algorithm that includes breath-test parame-
ters, age and other patient data to differentiate intrahepatic
inﬂammation (HAIa + HAIb + HAIc + HAId £ 4 vs >4 )
within chronic hepatitis C virus (HCV) patients with normal
alanine aminotransferase (NALT) achieved an area under
the curve (AUC) of 0.90. Setting a threshold at the point of
best agreement (at 83%), results in 82% sensitivity and 84%
speciﬁcity.Atthedatasetsprevalenceof68%thePPVis92%
and the NPV is 69%. Assuming a prevalence of 45.5% would
lead to a PPV of 82% and an NPV of 85%. Using Charles E.
Metz ROCKIT 1.1B2 provides the following results: binormal
parameters and area under the estimated ROC: a, 1.9574; b,
1.0126; area (Az), 0.9155; area (Wilc), 0.9021. Estimated
standard errors (SE) and correlation of these values: SE (a),
0.3453; SE (b), 0.2961; corr (a,b), 0.6238; SE (Az), 0.0305;
SE (Wilc), 0.0297. Symmetric 95% conﬁdence intervals: For
a, (1.2807, 2.6342); for b, (0.4322, 1.5930); asymmetric
95% CI for Az, (0.8389, 0.9609).
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Fig. 3 Receiver operating characteristic (ROC) curve
describing performance of the 67% patients where signiﬁ-
cant/nonsigniﬁcant ﬁbrosis was determined: Using Charles
E. Metz ROCKIT 1.1B2 provides the following results:
binormal parameters and area under the estimated ROC: a,
1.4888; b, 0.4950; area (Az), 0.9090; area (Wilc), 0.9153;
estimated standard errors (SE) and correlation of these
values: SE (a), 0.3047; SE (b), 0.1617; corr (a,b), 0.5744;
SE (Az), 0.0384; SE (Wilc), 0.0365; symmetric 95% CI: For
a, (0.8916, 2.0861); for b, (0.1782, 0.8118); asymmetric
95% CI for Az, (0.8091, 0.9636).
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724 G. Lalazar et al.Several noninvasive methods have been explored as tools
to assess the degree of liver ﬁbrosis in chronic HCV patients,
and some were also evaluated in patients with normal ALT.
These include a combination of serum tests such as the
AST⁄ALT ratio [18] or the AST⁄platelet ratio index [19]. To
date, two methods appear to be the most studied with the
goal of using them to supersede liver biopsy in the assess-
ment of liver ﬁbrosis. The ﬁrst is a patented artiﬁcial intelli-
gence algorithm (Fibrotest
 ; BioPredictive, Paris, France)
[20,21]. The second is a technique to measure in vivo liver
elasticity, based on one-dimensional transient elastography
(Fibroscan
 , EchoSens, Paris, France) [22,23].
The Fibrotest
  requires a blood sample and specialized
laboratory, which in turn translates into a lag time of several
days between test and result. Estimation of liver ﬁbrosis by
Fibrotest
  uses ﬁve parameters that were chosen by logistic
regression applied to a selection of basic serum biochemical
markers, with histological staging as the independent vari-
able [20]. Mean ALT values were three times the upper limit
of the reference range for males, and only 13% of the studied
patients had ALT within the normal range. Biochemical
markers were measured once on the day of biopsy, but
because ALT ﬂuctuates widely during the course of chronic
ROC
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1
1-Specificity
S
e
n
s
i
t
i
v
i
t
y
Fig. 4 By using the same proprietary algorithm developed
to differentiate signiﬁcant from nonsigniﬁcant ﬁbrosis, 65%
of the tested subjects would get an answer. Using Charles E.
Metz ROCKIT 1.1B2 provides the following results:
binormal parameters and area under the estimated ROC: a,
1.8231; b, 0.9943; area (Az), 0.9020; area (Wilc), 0.9005;
estimated standard errors (SE) and correlation of these
values: SE (a), 0.3697; SE (b), 0.2406; corr(a,b), 0.7157; SE
(Az), 0.0322; SE (Wilc), 0.0378; symmetric 95% CI for a,
(1.0984, 2.5477); for b, (0.5226, 1.4660); asymmetric
95% CI for Az, (0.8234, 0.9513).
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Dataset Inflammation
Assumed Threshold 
0–4 4–18
FOR 0.67  – + Total 
B
I
D – 17  82 5
+4 38  42 
Total 21 46 67
Assumed 
Prevalence:  45.50% 
Prevalence of Set:  68.66%
Sensitivity  82.61% 82.61% 
Specificity  80.95% 80.95% 
%
Agreement  82.09% 82.09% 
PPV  90.48% 78.36% 
NPV  68.00% 84.79% 
%
Prediction  82.09% 81.71% 
Fig. 5 A proprietary algorithm that includes breath-test
parameters, age and other patient data to differentiate int-
rahepatic inﬂammation (HAIa + HAIb + HAIc + HAId £ 4
vs > 4) applied on the 67% of the patient population as-
sessed by the ﬁbrosis algorithm, yields an area under the
curve (AUC) of 0.89. Leaving the threshold at the point of
best agreement (at 83%) found in the inﬂammation algo-
rithm, results in 83% sensitivity and 81% speciﬁcity. At the
datasets prevalence of 68%, the PPV is 91% and the NPV is
68%. Assuming a prevalence of 45.5%, this leads to a PPV
of 78% and an NPV of 85%. Using Charles E. Metz ROCKIT
1.1B2 provides the following results: binormal parameters
and area under the estimated ROC: a, 1.6781; b, 0.8979;
area (Az), 0.8941; area (Wilc), 0.8737; estimated standard
errors (SE) and correlation of these values: SE (a), 0.3529;
SE (b), 0.3125; corr(a,b), 0.5320; SE (Az), 0.0419; SE
(Wilc), 0.0419; symmetric 95% CI: for a, (0.9865, 2.3698);
for b, (0.2855, 1.5103); asymmetric 95% CI for Az,
(0.7882, 0.9552).
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Methacetin breath test in patients with HCV and normal ALT 725HCV infection, it is likely that only a few, if any, were HCV
carriers with NALT. In a subsequent Fibrotest
  prospective
validation study, participants needed documented elevated
serum ALT levels (at least 1.5 times the upper limit of nor-
mal) on three occasions within 6 months before enrolment.
There have been very few independent studies using Fibro-
test
 . In addition to inter-laboratory variations, these studies
have shown that in about 15–20% of patients, signiﬁcant
ﬁbrosis could be missed or conversely, signiﬁcant ﬁbrosis
could be diagnosed in the presence of minimal or no ﬁbrosis
[24]. In patients with Gilbert syndrome, or any acute
inﬂammation with high haptoglobin values, higher false-
positive and false-negative rates were found. In a recent
study of 40 patients with NALT, Fibrotest
  had an accuracy
of only 43%, with a sensitivity and speciﬁcity of only 64 and
31%, respectively (11). Both Fibrotest
  (measuring ﬁbrosis
stage in patients with chronic HCV or HBV) and ActiTest
 
(measuring necroinﬂammatory activity in patients with
chronic HCV or HBV) are dependent on inter-laboratory
variability of biochemical markers [25].
The Fibroscan
  provides a noninvasive method for
assessing liver ﬁbrosis but does not give information
regarding inﬂammation. In addition, it can be difﬁcult to
administer and may produce imprecise results in obese
patients. Measurement of liver elasticity so far has been
precluded by technical limitations and costs. With Fibro-
scan
 , a transmitted elastic wave can be temporally sepa-
rated from reﬂected elastic waves, making the technique less
sensitive to those boundary conditions (including body fat)
that tend to induce artefacts [22].
All the currently used noninvasive methods have a diag-
nostic accuracy that does not exceed 80–85% [26–29].
Thus, many patients still require a liver biopsy, and in those
classiﬁed without one, misdiagnosis is expected in at least
15–20% [30]. The ability of the MBT to accurately assess the
degree of intrahepatic inﬂammation and ﬁbrosis in patients
with NALT may add to its value in decision making for these
patients.
The clinical management of chronic HCV infection is
based on both patient and viral characteristics, and a liver
biopsy is often required to guide therapeutic decision mak-
ing. Paradoxically, patients with NALT, in whom liver
biopsy is particularly useful, are more reluctant to undergo
one. An attempt to increase the diagnostic performance of
noninvasive markers of liver ﬁbrosis by combining them in
sequential algorithms was recently suggested. Recently 190
patients with chronic HCV were evaluated for AST-
to-platelets ratio, Forns index and Fibrotest
  results at the
time of liver biopsy, and stepwise combination algorithms
were developed and validated prospectively in 100 addi-
tional patients. The data suggested that a stepwise combi-
nation of noninvasive markers of liver ﬁbrosis improves
diagnostic performance in chronic HCV, reducing the need
for a liver biopsy [31]. The data of the present study show
that by using an algorithm that includes breath-test
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Dataset Inflammation
Assumed Threshold 
0–4 4–18 
FOR 0.67  – + Total 
B
I
D – 10  41 4
+1 18 19 
Total 11 22 33
Assumed 
Prevalence:  45.50% 
Prevalence of Set:  66.67%
Sensitivity  81.82% 81.82% 
Specificity  90.91% 90.91% 
%
Agreement  84.85% 84.85% 
PPV  94.74% 88.25% 
NPV  71.43% 85.69% 
Fig. 6 A proprietary algorithm that includes breath-test
parameters, age and other patient data to differentiate int-
rahepatic inﬂammation (HAIa + HAIb + HAIc + HAId £ 4
vs > 4) applied on the 33% of patient population not
assessed by the ﬁbrosis algorithm yields an area under
the curve (AUC) of 0.96. Leaving the threshold on the point
of best agreement (at 83%) found in the inﬂammation
algorithm results in 82% sensitivity and 91% speciﬁcity. At
the datasets prevalence of 68% the PPV is 95% and the
NPV is 71%. Assuming a prevalence of 45.5%, this leads to
a PPV of 88% and an NPV of 86%. Using Charles E. Metz
ROCKIT 1.1B2 provides the following results: binormal
parameters and area under the estimated ROC: a, 3.5668;
b, 1.7357; area (Az), 0.9625; area (Wilc), 0.9628; esti-
mated standard errors (SE) and correlation of these values:
SE (a), 1.9626; SE (b), 1.5130; corr (a,b), 0.9003; SE (Az),
0.0419; SE (Wilc), 0.0314. Symmetric 95% CI: For a,
()0.2800, 7.4135); for b, ()1.2298, 4.7013); asymmetric
95% CI for Az, (0.7814, 0.9973).
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726 G. Lalazar et al.parameters, age and other patient data, 67% of liver biopsies
performed in the patient group could have been avoided.
This algorithm achieved an AUC of 0.92, with a sensitivity of
91% and a speciﬁcity of 88%.
As novel therapies for liver ﬁbrosis evolve, noninvasive
measurement of liver ﬁbrosis will be required to help manage
patients with chronic liver disease. The BreathID
  holds
several advantages as a noninvasive tool in this setting,
including not being limited by patient BMI or other patient
characteristics, such as the presence of Gilbert syndrome or
acute inﬂammatory condition. The test provides information
on both ﬁbrosis and inﬂammation. Future studies will
determine its correlation with the functional hepatic mass
and hepatic reserve along with the clinical course in these
patients.
The results of the current study suggest that the contin-
uous BreathID
  13C MBT is an accurate tool for identiﬁca-
tion of liver inﬂammation and ﬁbrosis in patients with
chronic HCV infection and normal ALT levels, and that its
use can avoid the need for a liver biopsy in two-thirds of
these patients. As such, it may prove to be a powerful,
noninvasive alternative for decision making in the man-
agement of this patient population.
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